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she role of plasma aldosterone concentration (PAC) in the
athogenesis of hypertension took an interesting turn a few
ears ago when several clinical trials claimed a higher
revalence of primary hyperaldosteronism in patients
hought to have primary or essential hypertension, particu-
arly those with resistant hypertension (1). A few clinical
rials demonstrated that, on the basis of these data, the
ddition of an aldosterone antagonist to the milieu of
ntihypertensive medications led to significant reduction
n blood pressure (BP) in patients with resistant hyper-
ension (2). The debate has continued among experts in
ypertension on the significance of PAC and the aldo-
terone/renin ratio (ARR) in the control and manage-
ent of hypertension (3).
See page 2171
Activation of the renin-angiotensin-aldosterone system is
ivotal in regulating and in maintaining arterial BP within
he normal range. Plasma renin and aldosterone levels are an
xample of a tightly coupled enzyme–hormone pair, the
ndividual components of which do not provide sufficient
nformation but when evaluated in combination as a ratio
rovide additional clues that guide further diagnostic work-
p. Renin secretion is regulated by several factors, including
enal baroreceptors and the macula densa, activation of
hich causes release of renin in response to a reduction in
enal perfusion pressure and decreased sodium chloride
elivery, respectively. Renin catalyzes the rate-limiting step
n the production of angiotensin II, an important regulator
f aldosterone synthesis by the zona glomerulosa of the
drenal glands. Aldosterone release results in increased
odium re-absorption at the tubular level of the distal
ephron and results in BP elevation. By contrast, in primary
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Department of Nephrology and Hypertension, Glickman Urological and
idney Institute, Cleveland Clinic Foundation, Cleveland, Ohio.yperaldosterone state there is unregulated release of excess
ldosterone from adrenal cortex resulting in excessive reten-
ion of salt and therefore hypervolemia, which suppresses
enin production (4,5).
Although initial research focused more on PAC excess
nd the primary hyperaldosterone state, 2 recent studies in
he past few months have contributed enormous informa-
ion on this topic and the effect on BP. Alvarez-Madrazo et
l. (6) recently demonstrated that ARR is continuously
istributed and is affected by several factors, including age,
ender, plasma potassium levels, and body mass index and is
trongly heritable. Their study also clarified that arbitrary
utoff points for elevated ARR do not identify patients with
rimary hyperaldosteronism, because normotensive individ-
als (although in a much lower proportion compared with
ypertensive individuals) might have similar elevation in
RR.
A study by Doi et al. (7) in an animal model has provided
trong evidence that, in addition to the aldosterone synthase
nzyme—universally accepted as a crucial molecule for
ldosterone synthesis—2 other enzymes, namely hydroxy-
elta5-steroid dehydrogenase, 3-beta- and steroid delta-
somerase-6 (HSD3b6) play a significant role in aldosterone
ynthesis. Disruption of cryptochrome genes that are re-
ponsible for HSD3b6 leads to excess aldosterone produc-
ion and the development of salt-sensitive hypertension in
ice. In this study, subsequent treatment with eplerenone,
n aldosterone antagonist, resulted in lowering of BP to
ormotensive levels.
Although the true prevalence of the primary aldosterone
tate continues to be debated, Tomaschitz et al. (8), in this
ssue of the Journal, take a step closer in further clarifying
he role of PAC excess as well as ARR levels in predicting
eripheral and central BP. Measurement of central aortic
P and evaluation of the role of the ARR on this measure-
ent add a unique value to this study.
Tomaschitz et al. (8) performed this study as part of the
udwigshafen Risk and Cardiovascular Health Study and
how a steady and significant relationship between the ARR
nd increasing peripheral and central BP. Individuals (n 
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New Insight Into Aldosterone/Renin Ratio and BP May 11, 2010:2181–2,056) with a mean age of 62.5 years, 31.9% of which were
omen, participated in this study; in addition to measure-
ent of their peripheral BP, their central aortic systolic BP
as measured as well, because they were undergoing cardiac
atheterization as part of the protocol for the primary study.
he PAC and plasma renin concentration were measured in
standardized fashion. A very high proportion of partici-
ants (32.8%) were found to have resistant hypertension on
he basis of criteria defined by international guidelines. In
he highest quartile of ARR, 12.8% of the participants had
ratio of more than 50 pg/ml/pg/ml, an arbitary threshold
onsidered by some hypertension experts as an indication
or further evaluation for primary hyperaldosteronism. In-
reasingly higher ARR deciles were associated with a steady
ise in peripheral and central systolic and diastolic BP and
ystolic aortic BP. This relationship persisted irrespective of
enal and cardiac function (on the basis of cystatin C and
-terminal pro-brain natriuretic peptide levels). In those
ho were normotensive, this ARR/BP relationship per-
isted with respect to diastolic BP when the levels were
elow 80 mm Hg. An interesting finding was that the
levated levels of plasma renin concentration at lower deciles
f ARR (10-fold higher in ARR decile 1 compared with
RR decile 10), although associated with high angiotensin
I levels, did not translate to high aldosterone levels, even
hen adjusted for antihypertensive medications and cardiac
nd renal dysfunction.
The authors deserve to be commended on moving beyond
iscussion on the relevance of the level of ARR in diagnosis
f primary hyperaldosteronism to evaluating the relation-
hip of ARR with BP levels. This study clearly identifies the
ole of increasing ARR in the pathogenesis of uncontrolled
ypertension. It is also the first study that addresses the
elationship of ARR with central BP, a parameter that is
eing increasingly accepted as the true BP experienced by
arget organs including the heart, brain, and kidney. Evi-
ence from recent clinical trials is accumulating that dem-
nstrates that not only is central BP a better predictor of
ardiovascular outcomes but that, with treatment, a lower
entral BP independent of peripheral BP is likely associated
ith better outcomes (9,10).
Furthermore, data from this study seem to justify a wider
nd more routine use of aldosterone antagonists in patients
ith elevated BP, to not only improve BP control but also
egate the deleterious effects of excess aldosterone on the
asculature in general and target organs in particular.
One important limitation of the study is its reliance on
Ps (peripheral and central) measured in the acute setting
hen the patients were undergoing cardiac catheterization.
K
plear evidence exists that BP is a dynamic entity and that
P measurements performed in less than ideal settings as
utlined by national guidelines might not represent true BP.
s the authors have emphasized, the cross-sectional design
f this observational study precludes conclusions with regard
o causality. However, intervention studies with a specific
ldosterone antagonist might provide some indication of
ausality.
Elevated ARR and PAC are associated with elevated
eripheral and central BPs. It is important for clinicians—
ather than dwelling on the controversy of whether a high
RR signifies the primary hyperaldosterone state—to rec-
gnize that an elevated ARR probably signifies an excess in
AC and that addition of an aldosterone antagonist could
oth improve BP control and optimize measures of arterial
tiffness as well.
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